Developing RNA-targeting medicines to treat previously incurable diseases
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.
WOBURN, Mass., November 5, 2024 — Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced today that preclinical data will be presented from its lead program, RGT-61159, at the 66th American Society of Hematology Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA.
Work with us
At Rgenta, our vision is aligned with one goal- to serve patients- by paving the way in precision medicine.
If you are bold, see the possibilities in front of you and strive to be impactful, we want to meet you!